Still, gefitinib or erlotinib therapy can be efficient even in NSCLC patients with wild-type EGFR, where the predictive biomarkers remain unknown [41], whereas the objective response rate here does not exceed 21% [42]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.